Scissor-like Au4Cu2 Cluster with Phosphorescent Mechanochromism and Thermochromism.

Reaction of [Au(tht)2](ClO4) (tht = tetrahydrothiophene), [Cu(CH3CN)4](ClO4), 3,6-di-tert-butyl-1,8-diethynyl-9H-carbazole (H3decz), and bis(2-diphenylphosphinophenyl)ether (POP) in the presence of triethylamine (NEt3) gave the cluster complex Au4Cu2(decz)2(POP)2 as yellow crystals. As revealed by X-ray crystallography, the Au4Cu2 cluster exhibits scissor-like structure sustained by two decz and two POP ligands and stabilized by Au-Cu and Au-Au interactions. The Au4Cu2 cluster shows bright yellow to orange photoluminescence upon irradiation at >300 nm, arising from 3[π (decz)→5d (Au)] 3LMCT (ligand-to-metal charge transfer) and 3[π→π* (decz)] 3IL (intraligand) triplet states as revealed by theoretical and computational studies. When it is mechanically ground, reversible phosphorescence conversion from yellow to red is observed owing to more compact molecular packing and thus stronger intermetallic interaction. Variable-temperature luminescence studies reveal that it displays distinct red-shifts of the emission whether the temperature is elevated or lowered from ambient temperature, suggestive of exceptional thermochromic phosphorescence characteristics.

Somatic variants of MAP3K3 are sufficient to cause cerebral and spinal cord cavernous malformations.

Cerebral cavernous malformations (CCMs) and spinal cord cavernous malformations (SCCMs) are common vascular abnormalities of the CNS that can lead to seizure, haemorrhage and other neurological deficits. Approximately 85% of patients present with sporadic (versus congenital) CCMs. Somatic mutations in MAP3K3 and PIK3CA were recently reported in patients with sporadic CCM, yet it remains unknown whether MAP3K3 mutation is sufficient to induce CCMs. Here we analysed whole-exome sequencing data for patients with CCM and found that ∼40% of them have a single, specific MAP3K3 mutation [c.1323C>G (p.Ile441Met)] but not any other known mutations in CCM-related genes. We developed a mouse model of CCM with MAP3K3I441M uniquely expressed in the endothelium of the CNS. We detected pathological phenotypes similar to those found in patients with MAP3K3I441M. The combination of in vivo imaging and genetic labelling revealed that CCMs were initiated with endothelial expansion followed by disruption of the blood-brain barrier. Experiments with our MAP3K3I441M mouse model demonstrated that CCM can be alleviated by treatment with rapamycin, the mTOR inhibitor. CCM pathogenesis has usually been attributed to acquisition of two or three distinct genetic mutations involving the genes CCM1/2/3 and/or PIK3CA. However, our results demonstrate that a single genetic hit is sufficient to cause CCMs.

Heteroctanuclear Au4Ag4 Cluster Complexes of 4,5-Diethynylacridin-9-One with Luminescent Mechanochromism.

Two heteroctanuclear Au4Ag4 cluster complexes of 4,5-diethynylacridin-9-one (H2L) were prepared through the self-assembly reactions of [Au(tht)2](CF3SO3), Ag(tht)(CF3SO3), H2L and PPh3 or PPh2Py (2-(diphenylphosphino)pyridine). The Au4Ag4 cluster consists of a [Au4L4]4- and four [Ag(PPh3)]+ or [Ag(PPh2Py)]+ units with Au4L4 framework exhibiting a twisted paper clip structure. In CH2Cl2 solutions at ambient temperature, both compounds show ligand fluorescence at ca. 463 nm as well as phosphorescence at 650 nm for 1 and 630 nm for 2 resulting from admixture of 3IL (intraligand) of L ligand, 3LMCT (from L ligand to Au4Ag4) and 3MC (metal-cluster) triplet states. Crystals or crystalline powders manifest bright yellow-green phosphorescence with vibronic-structured emission bands at 530 (568sh) nm for complex 1 and 536 (576sh) nm for complex 2. Upon mechanical grinding, yellow-green emission in the crystalline state is dramatically converted to red luminescence centered at ca. 610 nm with a drastic redshift of the emission after crystal packing is destroyed.

Elaborate Design of Ag8Au10 Cluster [2]Catenane Phosphors for High-Efficiency Light-Emitting Devices.

In this work, rational design of highly soluble and phosphorescent Ag-Au cluster complexes with exceptional [2]catenane structures is conducted using 1,8-diethynyl-9H-carbazole (H3decz) as a rigid U-shaped ligand with a distinguished hole-transport character. The self-assembly reaction of H3decz, Au+, and Ag+ generated phosphorescent Ag4Au6 cluster 1 (Φem = 0.22 in CH2Cl2) with H2decz- having a free ethynyl (-C≡CH) group. When the four free C≡CH groups in the Ag4Au6 complex 1 are further bound to four (PPh3)Au+ and four (PPh3)Ag+ moieties through M-acetylide linkages, the formation of Ag8Au10 cluster 2 not only eliminates nonradiative ethynyl C-H vibrational deactivation process but also improves dramatically the molecular rigidity so that the phosphorescent efficiency of the Ag8Au10 cluster 2 (Φem = 0.63) is nearly 3 times that of the Ag4Au6 cluster 1. The Ag8Au10 cluster structure is further rigidified using diphsophine Ph2P(CH2)4PPh2 (dppb) in place of PPh3 so that the phosphorescence of the Ag8Au10 cluster 3 (Φem = 0.77) is more efficient than that of 2. Making use of the Ag8Au10 clusters as phosphorescent dopants, high-efficiency solution-processed organic light-emitting diodes (OLEDs) were achieved with current efficiency (CE) and external quantum efficiency (EQE) of 47.2 cd A-1 and 15.7% for complex 2 and 50.5 cd A-1 and 14.9% for complex 3.

Silver(i) nanoclusters of carbazole-1,8-bis(acetylide): from visible to near-infrared emission.

A feasible synthetic approach to achieve Ag8, Ag16 and Ag29 silver(i) nanoclusters is reported by the use of 1,8-diethynyl-9H-carbazole (H3decz) as a directing ligand. The silver(i) nanoclusters exhibit room-temperature photoluminescence in both solution and solid state. The emission band shows stepwise red-shifts from visible to near-infrared region with the increase of cluster nuclearity following 2 (Ag8, λem = 571 nm) → 3 (Ag16, λem = 651 nm) → 4 (Ag29, λem = 916 and 875sh nm) in fluid CH2Cl2.

Pharmacokinetics of a novel microtubule inhibitor mHA11 in rats.

mHA11, a 2-amino-4-phenyl-4H-chromene-3-carboxylate analog, is a microtubule-targeting agent discovered by our group through the modification of the Bcl-2 inhibitor HA14-1. mHA11 exhibits cytotoxicities against tumor cells with nM IC50 values, whereas it has only a minimal effect on normal cells. We explored the plasma pharmacokinetics, tissue distribution, and excretion of mHA11 in rats using a liquid chromatography/tandem mass spectrometry (LC-MS/MS) method. Next, we identified the metabolites of mHA11 and assessed the influence of cytochrome P450 (CYP) isozymes on mHA11 metabolism. We also examined the in vitro stability in rat plasma and rat liver microsomes (RLMs), the blood-to plasma (B/P) ratio, and the inhibitory effect on CYP isozyme activities. After oral administration at 5, 15, and 45 mg/kg, mHA11 was absorbed and eliminated rapidly. There was a linear correlation between the area under the concentration-time curve (AUC0-∞) and the dose (R2 = 0.983). The bioavailability of mHA11 was 4.1% at the oral dose of 15 mg/kg mHA11 was extensively distributed in various tissues and exhibited a high penetration into the brain. No significant parent drug was detected in urine or bile, and only 0.74% was recovered in feces, whereas two demethylated metabolites, M1 and M2, were found in the urine and feces, and further studies showed that CYP2C19 primarily contributed to metabolites formation. mHA11 was stable in rat plasma but degraded significantly in RLMs; its B/P ratio was 1.05 in rat blood. In addition, mHA11 dose-dependently inhibited the activities of rat CYP isozymes, including CYP1A2, CYP2C6, CYP2C11, CYP2D2, CYP2E1 and CYP3A2. The present study is the first report on the disposition of mHA11 in rats and provides important data for further research and development of this inhibitor.

Peroxisome Proliferator-Activated Receptor γ Regulates the Expression of Lipid Phosphate Phosphohydrolase 1 in Human Vascular Endothelial Cells.

Lipid phosphate phosphohydrolase 1 (LPP1), a membrane ectophosphohydrolase regulating the availability of bioactive lipid phosphates, plays important roles in cellular signaling and physiological processes such as angiogenesis and endothelial migration. However, the regulated expression of LPP1 remains largely unknown. Here, we aimed to examine a role of peroxisome proliferator-activated receptor γ (PPAR γ ) in the transcriptional control of LPP1 gene expression. In human umbilical vein endothelial cells (HUVECs), quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) demonstrated that activation of PPAR γ increased the mRNA level of LPP1. Chromatin immunoprecipitation assay showed that PPAR γ binds to the putative PPAR-responsive elements (PPREs) within the 5'-flanking region of the human LPP1 gene. Genomic fragment containing 1.7-kilobase of the promoter region was cloned by using PCR. The luciferase reporter assays demonstrated that overexpression of PPAR γ and rosiglitazone, a specific ligand for PPAR γ , could significantly upregulate the reporter activity. However, site-directed mutagenesis of the PPRE motif abolished the induction. In conclusion, our results demonstrated that PPAR γ transcriptionally activated the expression of LPP1 gene in ECs, suggesting a potential role of PPAR γ in the metabolism of phospholipids.